Market Overview

Centrexion Therapeutics Appoints Dan Mendelson to its Board of Directors

Share:

Centrexion
Therapeutics Corporation
, a company focused on developing
non-opioid, non-addictive therapeutics for the treatment of chronic
pain, today announced that Dan Mendelson has joined its board of
directors. Mr. Mendelson served as associate director for health at the
Office of Management and Budget as part of the Clinton administration.
In this post, he oversaw the nation's full healthcare portfolio,
including Medicare, Medicaid, the National Institutes of Health, the
Centers for Disease Control, and the Food and Drug Administration. Mr.
Mendelson is also the founder of and now current advisor to Avalere
Health, a vibrant community of innovative thinkers dedicated to solving
the challenges of the healthcare system through data-driven advisory
services and business intelligence products.

"Dan is known for his astute insights on the fast-changing health policy
environment," said Sol Barer, Ph.D., chairman, Centrexion Therapeutics
board of directors. "His expertise in helping business leaders in the
healthcare world anticipate these changes and craft strategies to
succeed in the area of biomedical innovation will bring valuable
perspective to our board as we advance our mission to improve the lives
of people living with chronic pain."

"At Centrexion Therapeutics, we are committed to developing new,
non-opioid drugs to provide better treatments to those living with
chronic pain that don't cause dependency or addiction," said Jeffrey B.
Kindler, chief executive officer of Centrexion Therapeutics. "Dan's
expertise and experience perfectly align with our mission to bridge the
safety and efficacy gaps in current approaches to chronic pain
management, and we are thrilled to have him join our board and support
the continued growth of Centrexion."

"Successfully addressing the opioid crisis will require the development
of safe and effective pain management alternatives beyond traditional
opioids," said Mr. Mendelson. "The potential social, economic, and
medical impacts of Centrexion's innovative platform and exciting drug
development efforts are significant, and I'm thrilled to be a part of
it."

Mr. Mendelson brings substantial healthcare expertise and leadership to
the Centrexion board of directors. Currently, Mr. Mendelson is advisor
to Avalere Health, a group which he founded in 2000 and grew organically
as chief executive officer until 2015, when he sold the company to
Inovalon Holdings (INOV). Prior to that, Mr. Mendelson served as
associate director for health at the Office of Management and Budget
where he oversaw numerous government healthcare programs and agencies,
as well as the development of numerous initiatives in health information
technology and medical error prevention, the electronic disease
surveillance system, and policies in reimbursement and technology
assessment. Mr. Mendelson presently serves on the board of Champions
Oncology, as well as on the advisory boards for Faster Cures, the
Alliance for Health Policy, and the Duke Margolis Center. In addition,
he is a founding member of Guidon Partners, an investment management
group, and is executive in residence at the Fuqua School of Business at
Duke University.

Mr. Mendelson received his undergraduate degree in economics and viola
performance from Oberlin College and his master's degree in public
policy from the Kennedy School of Government at Harvard University.

About Centrexion Therapeutics

Centrexion Therapeutics Corp. is focused on advancing the treatment of
chronic moderate to severe pain with one of the largest, exclusively
pain-focused pipelines of non-opioid, non-addictive therapies in active
development. Centrexion Therapeutics recognizes the needs of over a
quarter of a billion people living with chronic pain worldwide, and aims
to develop new, safer and more effective therapies that overcome the
limitations and challenges associated with current pain treatments.
Founded by world-renowned leaders in drug development and well-funded by
key investors, Centrexion Therapeutics is building a pain treatment
powerhouse to address the substantial and growing global chronic pain
epidemic. For more information about Centrexion Therapeutics, visit http://www.centrexion.com.

View Comments and Join the Discussion!